Treatment Recommendation for Anxiety in Children and Adolescents
For children and adolescents with prominent anxiety contributing to dysfunctional breathing, prescribe a selective serotonin reuptake inhibitor (SSRI) as first-line pharmacologic treatment, particularly for moderate to severe presentations. 1
Treatment Algorithm
Severity-Based Approach
Mild to Moderate Anxiety:
- First-line: Cognitive-behavioral therapy (CBT) alone 1
- Alternative: SSRI monotherapy if quality CBT is unavailable 1
Moderate to Severe Anxiety:
- Preferred: Combination treatment (CBT + SSRI) - this is more effective than either treatment alone 1
- Alternative: SSRI monotherapy if CBT unavailable 1
Specific SSRI Considerations
The 2020 AACAP guideline establishes SSRIs as having "considerable empirical support as safe and effective short-term treatments" 1. While multiple SSRIs have demonstrated efficacy in clinical trials, most lack FDA approval for pediatric anxiety disorders. The evidence supports using SSRIs as a medication class based on their shared mechanism of action 2, 3.
Key implementation points:
- Start at low doses and titrate gradually based on response
- Monitor systematically using standardized symptom rating scales
- Ensure parental oversight of medication regimens 1
- Watch for treatment-emergent adverse effects including suicidal ideation (particularly in patients up to age 24), behavioral activation, and serotonin syndrome 1
Second-Line Option: SNRIs
Serotonin-norepinephrine reuptake inhibitors (SNRIs) can be considered as an alternative pharmacologic option 1. Duloxetine is the only SNRI with FDA approval for generalized anxiety disorder in children ≥7 years old 1. SNRIs have "some empirical support" but less robust evidence than SSRIs 1.
SNRI-specific considerations:
- Monitor blood pressure and pulse (SNRIs associated with sustained hypertension and increased cardiovascular parameters) 1
- Common side effects include fatigue/somnolence, diaphoresis, GI symptoms 1
- May be particularly useful when SSRIs have failed or are not tolerated
Critical Caveats
Avoid benzodiazepines: Despite historical use, there is insufficient evidence of efficacy in pediatric anxiety disorders, and they carry risks of paradoxical reactions and potential for misuse with long-term use 2, 4. The guidelines explicitly note insufficient data to support benzodiazepine recommendations 1.
Combination therapy superiority: The Child-Adolescent Anxiety Multimodal Study (CAMS) demonstrated that combination CBT plus sertraline improved anxiety symptoms, global function, treatment response, and remission rates compared to either treatment alone (moderate strength of evidence) 1. This makes combination therapy the preferred approach when resources permit, as initial treatment response strongly predicts long-term outcomes 1.
Monitoring requirements:
- Assess for suicidal ideation/behavior, particularly during initial treatment and dose changes
- Screen for behavioral activation, agitation, or mood switching
- Evaluate treatment response at regular intervals using validated measures
- Consider psychiatric referral for severe presentations or when multimodal treatment is needed 5
The evidence consistently supports SSRIs as first-line pharmacotherapy across multiple recent guidelines and research studies 5, 2, 3, 6, 7, with the 2020 AACAP guideline providing the most comprehensive and authoritative recommendations for this population.